Study for the antithrombotic therapy of rivaroxaban and clopidogrel after PCI in Chinese patients with acute coronary syndrome complicated with atrial fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000030143

Enrollment

Unknown

Registered

2020-02-24

Start date

2019-01-01

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Case series:Rivaroxaban (15mg 1/ d) + clopidogrel (75mg 1/ d)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. It was confirmed as nvaf by cardiac ultrasound and electrocardiogram; 2. Anticoagulant therapy was required by chads2-vasc score; 3. implantation of drug-eluting stents (DES).

Exclusion criteria

Exclusion criteria: 1. severe hepatic and renal dysfunction (CrCl < 30ml/min; 2. clinically significant active bleeding or diseases with significant bleeding risk; 3. combined use of cyclosporin, systemic ketoconazole, itraconazole, tacromeus and creedalon;Antiplatelet drugs and anticoagulant drugs contraindicated, such as thrombocytopenia, severe bleeding; 4. allergic to drugs; 5. Poor compliance, INR and other observation indicators can not be regularly followed up as prescribed by the doctor.

Design outcomes

Primary

Measure	Time frame
Renal function;	—

Countries

China

Contacts

Public ContactJidong Zhang

The Second Hospital of Hebei Medical University

zhangjidong78@163.com+86 15803210731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026